

IR/PR Contact:
Tim Allison
LaVoie Group
978-745-4200 X 102
tallison@lavoiegroup.com



FOR IMMEDIATE RELEASE:

**EYEGATE PHARMA TO PRESENT AT
UPCOMING INVESTOR CONFERENCES**

Waltham, MA, – April 15, 2008 – EyeGate Pharma, a privately held, specialty pharmaceutical company using iontophoresis technology to safely and non-invasively deliver therapeutics into the front and back of the eye for treating serious ocular diseases, today announced that Stephen From, President and CEO of EyeGate, will present at the *First Annual BIO National Venture Conference* and the *Rodman and Renshaw 5th Annual Global Healthcare Conference*. Mr. From will be available for one-on-one meetings during both conferences.

The *First Annual BIO National Venture Conference* will take place on April 22-23, 2008 at the Hyatt Regency Cambridge with Stephen From's presentation taking place on April 22 at 3:45 PM. For more information, please visit <http://bnvc.bio.org/opencms/BioVenture/2008/index.jsp>

Stephen From will also present at the *Rodman and Renshaw 5th Annual Global Healthcare Conference* taking place May 19-20, 2008 at Le Meridien Beach Plaza Hotel at the Sea Club, with his presentation taking place on May 19, at 9:20 AM in the Zephyr Salon (4th floor). For more information, please visit <http://www.rodmanandrenshaw.com/conferences?id=18>

About EyeGate Pharma

EyeGate Pharma was founded in 1999 with technology licensed from Bascom Palmer Eye Institute at the University of Miami. EyeGate's transscleral (across the sclera, or white protective outer membrane of the eye) iontophoresis delivery platform, the EyeGate[®] II Delivery System, was developed to safely deliver a wide range of therapeutics to both the anterior (front) and posterior (back) chambers of the eye. An 89-patient clinical study, using the company's first-generation delivery device, demonstrated significant decreases in inflammatory markers and concurrent increases in visual acuity. A typical application takes less than five minutes and has been shown to be extremely well tolerated in patients suffering from severe uveitis and other inflammatory ocular diseases. Clinical studies utilizing the EyeGate[®] II Delivery System are scheduled to begin in the first half of 2008. For more information please visit www.eyegatepharma.com.

#